Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008733 | 0.89 | BCHE (0.45) | BCHENPC1RAB9AF2RL3HTR1A | |
| SCHEMBL593890 | 0.77 | BCHE (0.54) | BCHEAHRKEAP1PDPK1BACE1 | |
| SCHEMBL4317622 | 0.75 | BCHE (0.49) | BCHEAHRKEAP1PDPK1BACE1 | |
| SCHEMBL859924 | 0.75 | BCHE (0.51) | BCHEAHRKEAP1HTR1AHTR1D | |
| SCHEMBL12543495 | 0.75 | AHR (0.47) | BCHEAHRKEAP1PDPK1BACE1 | |
| SCHEMBL1544900 | 0.75 | AHR (0.47) | BCHEAHRKEAP1NPC1RAB9A | |
| SCHEMBL837602 | 0.73 | L3MBTL1 (0.51) | BCHEAHRHTR1ATDP1 | |
| SCHEMBL837560 | 0.73 | BCHE (0.48) | BCHEAHRKEAP1PDPK1BACE1 | |
| SCHEMBL837183 | 0.73 | BCHE (0.50) | BCHEAHRHTR1DHTR1BTDP1 | |
| SCHEMBL1582742 | 0.73 | HTR1B (0.51) | HTR1AHTR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068951-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| EP-4504699-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2025-02-12 | — | — | EP | claimed |
| WO-2023187715-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-05 | — | — | WO | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4719404-A2 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | Stealth BioTherapeutics Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4618978-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025101939-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025080946-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4532503-A1 | HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025068951-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| EP-4504699-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004050085-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| EP-0469833-B1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY CO ELI (GB) | 1999-09-08 | — | — | EP | disclosed |
| US-5622969-A | ADMINISTERING TO HUMAN OR ANIMAL SUFFERING FROM ALLERGIC REACTION OF PULMONARY SYSTEM AND OTHER INFLAMMATORY DISORDERS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5569764-A | USEFUL FOR TREATING ALLERGIC REACTIONS OF PULMONARY SYSTEM, ALLERGIC SKIN DISEASES, RHEUMATIC FEVER, CYSTIC FIBROSIS, AND VASCULAR DISEASES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5486612-A | FOR TREATING DISEASES WHICH LEUKOTRIENES MEDIATE | ELI LILLY AND COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| EP-0658554-A1 | N-benzyl dihydroindole LTD4 antagonists | ELI LILLY AND COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5281593-A | Pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1994-01-25 | — | — | US | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | HTR3C, HTR2C, CYP3A5 | BCHE 745/4885AHR 276/4885KEAP1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.